Employee Login
ICMR - National AIDS Research Institute
Logo Thing main logo
Logo Thing main logo

Profile

DR SHEELA  V. GODBOLE
Name : DR SHEELA V. GODBOLE
Designation : Director
Division : Epidemiology
Email ID : [email protected] , [email protected]
Area Of Interest : Impact Evaluation, Clinical Trials, HIV and STI Epidemiology, Surveillance & Estimations, HIV-Cancer, Health Systems, Elimination of Mother to Child Transmission (HIV/Syphilis)
Completed and Ongoing Projects

Ongoing Research Support:

  1. A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Immunogenicity and Safety of Single dose of Dengue Tetravalent Vaccine, Live Attenuated (Recombinant, Lyophilized) – “DengiAll” of Panacea Biotec Limited in Healthy Indian Adults – Principal Investigator
  2. Sentinel survey of the high-risk population through community based organizations for the detection of Human MPOX virus infection in India - Mentor
  3. ‘WHO-ICMR SOLIDARITY TRIAL PLUS –-India titled “An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are receiving the local standard of care” (ICMR ) – Principal Investigator
  4. “Prevalence of Select Sexually Transmitted infections and Reproductive Tract infections among selected High Risk Groups: MSM, FSW, IDU in India” (NACO, GoI) – Principal Investigator
  5. HIV Sentinel Surveillance (Western and Central India): Program-research (NACO, GoI) – Principal Investigator
  6. In STI Sentinel Surveillance at DSRC, ICMR-NARI acting as Nodal Agency – Principal Investigator
  7. ICMR/SII-COVOVAX: A phase 3, observer-blind, randomized, controlled study to determine the safety and immunogenicity of Covovax [Sars-CoV-2 recombinant spike protein nanoparticle vaccine (Sars-CoV-2 rS) with Matrix-M1™ adjuvant] in Indian adults., PI /Co-PI (ICMR )

Completed Research Support: (last 10 years only)
    1. ‘WHO-ICMR SOLIDARITY TRIAL PLUS –-India titled “An international randomized trial of
     additional treatments for COVID-19 in hospitalized patients who are receiving the local standard
     of care” (ICMR ) – Principal Investigator
    2. ICMR/SII-COVOVAX: A phase 3, observer-blind, randomized, controlled study to determine the
    safety and immunogenicity of Covovax [Sars-CoV-2 recombinant spike protein nanoparticle
    vaccine (Sars-CoV-2 rS) with Matrix-M1™ adjuvant] in Indian adults., PI /Co-PI (ICMR )
    3. The ART Impact Evaluation- India Study (ARTIE-India): Evaluation of Impact of Antiretroviral
    Therapy under the National AIDS Control Programme in India’ (2017-2020)
    4. An assessment of feasibility of operationalization of ‘Early or Immediate ART’ to HIV infected
    partners as a combination intervention among HIV sero-discordant couples in India.(2016 -2019)
    5. In-country data validation for Elimination of mother-to-child transmission of HIV and Syphilis in
    Six Indian states, 2017. Phase I: Maharashtra (2017)
    6. HPTN 052:A Randomized Trial to Evaluate the Effectiveness of Antiretroviral Therapy plus HIV
    Primary Care versus HIV Primary Care alone to prevent the Sexual Transmission of HIV-1 in
    Sero-discordant Couples. (2011-2016)
    7. Utility of Prevention-of-Mother-to-Child HIV Transmission Program Data for HIV Surveillance
    (2015 and 2017)
    8. Relation Between Genetic Markers of Drug Resistance and Susceptibility Profile of N.
    gonorrhea strains’- A study in 4 centres in India (2014-2015)
    9. ACTG 5282:A Randomized, Phase II Trial to Compare an HPV Test-and-Treat Strategy to a
    Cytology-based Strategy for Prevention of CIN 2+ in HIV-infected Women (2013-2015)

Education Qualifications :
1) MD (Dermatology, Venereology, and Leprology), 1992, Byramjee Jeejeebhoy (B.J.) Medical
College, University Of Pune.
2) MBBS (Medicine and Surgery), 1988, Byramjee Jeejeebhoy (B.J.) Medical College, University of
Pune (Internship completed in 1989)
3) PG Diploma in Epidemiology, 2014, Public Health Foundation of India

Dr. Sheela Godbole MD is the Director of ICMR-National AIDS Research Institute (ICMR-NARI), Pune and
holds additional charge as Director of the ICMR-National Institute of Virology, Pune as well. An alumnus
of Byramjee Jeejeebhoy Medical College (BJMC), Pune, she obtained her MD in 1992.


A clinician by training, she spent nearly a decade caring for persons with HIV and STI’s which led her to a
full time career in research and she joined the Indian Council of Medical Research in 2001. She has been
the Principal Investigator of many large studies and trials in India and site PI for multinational trials with
the HIV Prevention and the AIDS Clinical Trials Networks. She was the National Coordinator for the
WHO-Solidarity Trial. She serves on various national committees & technical resource groups for
Government of India and is a WHO Technical Advisory Group member. In addition to her administrative
responsibilities & leading over a 100 scientists in two institutions, she continuous her research work in
HPV, HIV and Dengue. Her work has been published in leading journals like New England Journal of
Medicine, Lancet, Lancet-ID, Journal of AIDS and Indian Journal of Medical Research.


An experienced clinician researcher, a committed leader, communicator and mentor. She plans to guide
the institute towards newer horizons in clinical trials and other clinical virologic research.


Research Areas: Clinical Trials for treatment and prevention of HIV, COVID, HPV and other viral disease,
clinical-epidemiological research (HIV, STI surveillance, HIV-cancer), Program implementation research,
prevention and care, elimination of vertical transmission of HIV and Syphilis.

Personal Statement

An experienced clinician-researcher, a leader, passionate communicator with strong technical, grant-
writing, project management-implementation and administrative skills, I work well under pressure.
As a consultant caring for persons with HIV and STI in the pre-antiretroviral treatment era in India, I was
drawn to fill gaps in HIV, and STI care through research. For over two decades, I have led clinical Trials
for HIV prevention and treatment (antiretrovirals) and most recently COVID-19 and am about to initiate
national phase 3 trial for Dengue vaccine in India. I have also focused on clinical-epidemiological
research in HIV, STI’s, HPV, HIV& cancer. Additionally have been involved collaboratively in basic
science research in HIV immunology, HIV drug resistance and genetic basis of antimicrobial resistance of
N.gonorrhoeae in India. I led a research clinic providing care for sexually transmitted infections and HIV
for over 15 years.
I have contributed to India’s commitment to eliminate Mother to Child Transmission of HIV and Syphilis
in 2020 as a key member of the National Core Group formulated by the Ministry and by conducting a
unique Data Validation study that identified key gaps and action points for NACO and RMNCHA+
programs. I recently completed the first evaluation of the impact of the ‘Free antiretroviral treatment
(ART) program’ of the Government of India, which is the largest financial outlay under the NACP and
set up a strong nationwide collaboration for the same.
I have successfully written, received and implemented many national and internationally funded
extramural research grants and currently manage large project budgets and lead collaborations with
multiple partner institutes in India (ICMR and non-ICMR). As Investigator of Record and later grantee PI
for the Phase III Randomised Controlled Clinical Trial for HIV prevention (HPTN 052) since 2008, I
played a major role in setting up systems to ensure good implementation of clinical trials at ICMR-NARI.
The years of experience as a Clinical Research Site Leader and later on as the Principal Investigator of the
NIH USA-funded NARI Clinical Trial Unit (CTU) honed my scientific temperament and people
management skills.

I have successfully been able to liaise and interact with State AIDS Control Societies, state health
systems, and medical colleges especially microbiology, community medicine and medicine departments
across India, and other institutions as well for research studies.

I currently serve on the WHO Technical Advisory Group for STI research priority setting and have served
on various international scientific committees. Through participation in ‘expert consultations’, technical
resource groups and guideline development committees, I provide technical support to Government of
India’s National AIDS Control Programme (NACP). I am responsible for HIV Sentinel Surveillance in 5
states and 2 Union Territories of Western India and have helped test out newer methods of surveillance
that were adapted nationally. In response to the COVID-19 pandemic, I am currently leading the ICMR-
India-WHO Solidarity trials for treatment options for Hospitalised COVID Patients as the National
Principal Investigator and coordinator and played a lead role for bridging vaccine trials. I led the initiation
of the India- adult bridging trial for ‘Covovax’ COVID vaccine on behalf of ICMR in 2020-21 and this
has now received Emergency Use Authorization from the Drugs Controller General of India. Currently I
am Director of ICMR-National AIDS Research Insitute in Pune and steering the institute into research
beyond HIV and STI’s. I am also Director in Charge of National Insitute of Virology (ICMR-NIV).

Awards and Honours
  • Phoenix Leading Lady Award for Excellence in Research in Maharashtra, March 2017
  • Selected as an ICMR fellow for the “Collaborative Indo-Swedish Public Health Initiative for Research Excellence” (INSPIRE) Indo-Swedish Program in 2011-12
  • “Young Achievers Award for Women”: for contributions in the field of Health and Medicine in Pune City over the last decade. 4th January 2003 in Pune, All India Women’s Conference
  • “Best Participant award”: WHO Disease Burden Workshop 2001.
  • “A. C. Parikh award for Best Case Paper presentation”, presented by Indian Association of Dermatologists and Venereologists Maharashtra Branch 1992.
  • Scientific Breakthrough of 2011”: The paper “Prevention of HIV-1 Infection with Early Antiretroviral Therapy” published in New England Journal of Medicine July 18 2011, was identified as Scientific Breakthrough of 2011 in December 2011 by the prestigious journal ‘Science’. I am a Co-Author on the mast head of this paper. This paper has become a citation classic with nearly 5000 citations


Membership of Professional / Advisory Bodies / Committees:
1. WHO Technical Advisory Group (TAG) on Sexually Transmitted Infection (STI) research
priority setting- 2021
2. WHO and UK Government ‘Round Table on the international clinical trials infrastructure’- 2021
3. WHO ad hoc consultation COVID-19 therapeutics Knowledge gaps and research priorities
4. India Task Force Lancet COVID-19 Commission

5. WHO Technical Advisory Group (TAG) on Sexually Transmitted Infection (STI) research
priority setting- 2021
6. WHO and UK Government ‘Round Table on the international clinical trials infrastructure’- 2021
7. WHO ad hoc consultation COVID-19 therapeutics Knowledge gaps and research priorities
8. India Task Force Lancet COVID-19 Commission


National Level technical and advisory committees constituted by National AIDS Control
Organization (MoH&FW) GOI for the National AIDS Control Program (NACP)
1. Technical Working Sub-Group for Strategic Plan and Framework for EVTHS- Lead 2022
onwards
2. Technical Resource Group for NACO Lab services- Chair, 2022 onwards
3. Technical Resource Group for Female Sex Workers (FSW), Member 2021 onwards
4. Technical Resource Group on Surveillance and Epidemiology Member- 2021 onwards
5. Co-Chair, National Sub-Group for STI Surveillance, 2021 onwards
6. National Sub-Group for HIV Burden Estimations - 2021 onwards
7. National Working Group- District Level HIV Estimations 2019-20,
8. Technical Resource Group for HIV Estimations 2017-18- Member
9. Technical Resource Group for HIV Sentinel Surveillance 2017, - Member
10. National Consultation-Elimination of Mother to Child Transmission of HIV -Private Sector
participation, -Member
11. National Core Group on Elimination of Mother to Child Transmission of HIV and Syphilis
12. Subcommittee for development of Verification and Validation protocols for Elimination of Mother
to Child Transmission of HIV and Syphilis (EMTCT) NACO MoH&FW, GOI: Member
13. Technical Resource Group for Prevention of Parent to Child Transmission of HIV, NACO,
MoH&FW, GOI- Member
14. National Strategic Plan (2017-24) development (NACO road map): for prevention and
elimination of HIV/AIDS in India- Technical Sub-Committee Monitoring, Evaluation and
Surveillance: Member
15. National Strategic Plan (2017-24) development: NACO road map for prevention and elimination
of HIV/AIDS in India constituted by NACO MoH&FW, GOI: Technical Sub-Committee for a.
EMTCT of HIV & b. HIV-TB: Member
16. National HIV Testing Guidelines Writing Group: Technical Expert and Sub Committee member
Dec 2015 – July 2016. (The guidelines were published in Dec 2016)
17. Regional STI Centre National Mentoring Committee: Committee was constituted in September
2012- Member
18. NACO Technical Resource Group’s for NACP IV planning: Member of following sub-groups-
i. Sexually Transmitted Infections Working group and STI Surveillance

ii. Research and Evaluation: Strategic Information Management Unit

19. NACO Technical Resource Group’s for NACP IV planning: Member of following sub-groups-
i. Sexually Transmitted Infections Working group and STI Surveillance
ii. Research and Evaluation: Strategic Information Management Unit

Consultations by WHO/ UNAIDS/GOI
1. Expert consultation -Newer Methods of Surveillance and HIV estimations in India, 2018
2. Expert Consultation for HIV Surveillance and Estimations 2016: Member and Resource Person.
3. Expert Consultation for HIV Testing: WHO and NACO Nov 2015 Member
4. Expert Consultation for the Development of a Strategy towards Elimination of Congenital Syphilis
(ECS) 2013 : Member


Ethics Committees
1. Ethics Committee: National Institute of Virology –Member
2. Ethics Committee: UDIRT, Maharashtra University of Health Sciences (MUHS), Nashik,
Maharashtra. February 2006-8

Other International:
1. India Task Force- Lancet COVID Commission (Member)
2. Prevention Science Working Group- HIV Prevention Trial Network, DAIDS NIH USA
(completed)
3. Women’s Health Committee, AIDS Clinical Trials Network, DAIDS NIH USA (completed)
4. Women at Risk (WaTR) Scientific Committee of HIV Prevention Trial Network, DAIDS NIH
USA (completed)
5. Performance Evaluation Committee, AIDS Clinical Trials Network, DAIDS NIH USA
(completed)


Professional Bodies:
1. Indian Association of Preventive & Social Medicine (IAPSM)- Life member
2. Indian Association of Dermatologists, Venereologists and Leprologists (IADVL) - Life member
3. Indian Medical Association- Life Member




Work Experience

 

Position*

Institution

From

To

Scientist ‘G’ and Director

ICMR-National AIDS Research Institute (ICMR-NARI), Pune

19 May 2022

Ongoing

Scientist F

Head of Division

Epidemiology and Biostatistics,

ICMR-National AIDS Research Institute (ICMR-NARI), Pune.

 

ICMR-NARI is an institute of the Indian Council of Medical Research, Department of Health Research, Government of India

1 September 2017

18 May 2022

Scientist E

Head of Division

1 September 2012

31 August 2017

Scientist D

18 Mar 2008

31 August 2012

Senior Research Officer

16 Oct 2006

17 March 2008

Research  Officer

20 Sep 2001

15 Oct 2006

Lady Medical

 Officer (Part-Time)

NARI Projects- Acute Pathogenesis of HIV Infection [RO1]

June

1999

19 September 2001

‘Consultant Panel Doctor': 

( Skin & STD)

TATA Engineering and Locomotive Company Limited (TELCO), Pune

April 1996

September 2001

Panel Doctor

Sanjeevan Hospital Pune

1995

September 2001

Hon. Consultant in Skin & STDs and DNB Training

Deendayal Memorial Cancer Hospital, Pune.

June 1993

April 1998

Consultant Dermatologist

Self Employed                                      (Private Practice)

1993

September 2001

*Actively involved in clinical care of persons at risk of or with HIV as a clinician until recently

Major Academic and Research Achievements:

Research Experience:

Dr. Godbole has led many nationally and internationally funded research projects/clinical trials as Principal Investigator over two decades

Research in a Lead Role: (N=24 Projects)  

As Principal Investigator (PI) / Investigator of record (IoR) /Nodal Officer

List of Grant Recieved

 

Sr.No

Project Name

Funding Agency

Ongoing/ completed

1.                  

WHO Solidarity Plus trial:
An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care

 

Principal Investigator

World Health Organization - India

Ongoing

2.                  

INDIA ICMR Solidarity trial:
An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care

 

Principal Investigator

Indian Council of Medical Research

Ongoing

3.                  

Prevalence of Select Sexually Transmitted infections and reproductive Tract infections among selected High Risk Groups: MSM, FSW, IDU in India

 

Principal Investigator

National AIDS Control Organization

Ongoing

4.                  

WHO Solidarity trial:
An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care

Principal Investigator

 

Completed

5.                  

SII-COVID-19: A phase 2/3, observer-blind, randomized, controlled study to determine the safety and immunogenicity of COVOVAX [SARS-COV-2 recombinant spike protein nanoparticle vaccine (sars-cov-2 rs) with matrix-m1™ adjuvant] in Indian adults –

 

 Co- Principal Investigator

Indian Council of Medical Research

Ongoing

6.                   

HIV Sentinel Surveillance (Western and Central India): Program-research

 

Focal Person / Nodal Officer

National AIDS Control Organization

Ongoing

 

Completed Projects

7.                   

Behavioural Sentinel Surveillance

 

Focal Person / Nodal Officer

National AIDS Control Organization

Completed

8.                   

Evaluation of Impact of Antiretroviral Therapy under the National AIDS Control Programme in India’ -- The ART Impact Evaluation- India Study (ARTIE-India)

Principal Investigator

National AIDS Control Organization

Completed

9.                   

An assessment of feasibility of operationalization of ‘Early or Immediate ART’ to HIV infected partner as a combination intervention among HIV sero-discordant couples in India.

Principal Investigator

National AIDS Control Organization

Completed

10.               

In-country data validation for Elimination of mother-to-child transmission of HIV and Syphilis in Six Indian states, 2017. Phase I: Maharashtra

Principal Investigator

World Health Organization

Completed

11.               

Feasibility Study of HIV Database and Cancer Registry Match

India- Principal Investigator

UCLA-CFAR,NIH Extramural

Completed

12.               

Relation Between Genetic Markers of Drug resistance and Susceptibility Profile of N. gonorrhoeae strains’- A study in 4 centres in India

Principal Investigator

ICMR-Extramural

Completed

13.               

Clinical Trial Unit

Principal Investigator

Co-Investigator (previously)

NIH, USA

Completed

14.               

HPTN 052:A Randomized Trial to Evaluate the Effectiveness of Antiretroviral Therapy plus HIV Primary Care versus HIV Primary Care alone to prevent the Sexual Transmission of HIV-1 in Sero-discordant Couples

Investigator of record and Grantee PI

NIH, USA

Completed

15.               

Prevalence of anal HPV infections and associated abnormalities in HIV infected women: A feasibility study

ICMR-NARI Intramural

Completed

16.               

Statistical Concepts for Clinical Research a Non-Mathematical Workshop-training for Clinicians

Principal Investigator

Indian Council of Medical Research

Completed

17.               

ACTG 5282: A Randomized, Phase II Trial to Compare an HPV Test-and-Treat Strategy to a Cytology based Strategy for Prevention of CIN 2+ in HIV-infected Women

 

Principal Investigator

 

NIH (CTU grant)

(Extramural)

Funding Incorporated in CTU ATCG-Core Grant

Completed

18.               

“Study of Incidence, Morbidity, Mortality, Immunology and Risk factors for complications of pandemic H1N1 influenza like illnesses (ILI) in HIV infected individuals, at Pune India”.

Principal Investigator

ICMR-NARI

Intramural

Completed

19.               

Evaluation of provider, patient and pharmacy knowledge, attitudes and practices regarding  HIV care and use of antiretroviral (ARV) therapy in Pune, India

 Principal Investigator

ICMR-NARI

Intramural

Completed

20.               

Prevalence of HIV in Cutaneous Adverse Drug Reactions: (ADR Study)

Principal Investigator

ICMR-NARI

Intramural

Completed

21.               

Disease Burden Estimation for HIV/AIDS for Pune District

Principal Investigator

ICMR-NARI

Intramural

Completed

 

Research in a Collaborative/Supportive Role- Co-Investigator

 

22

Onwards

 

 

 

Dr. Godbole has been Co-Investigator in over 20 studies.

 

These include clinical trials for microbicides and antiretroviral treatment, epidemiologic studies, Impact evaluation, operations research and laboratory studies related to immunology, HIV virology and microbiology.

 

Conference/Training/Workshop Attended

Conferences/Trainings/Workshops Attended

Abstracts Presented in Conferences since 2008

International: 22

National: 11

National Level technical and advisory committees:

  1. Technical Resource Group for HIV Estimations 2017-18- National AIDS Control Organization (NACO) MoH&FW, GOI- Member
  2. Technical Resource Group for HIV Sentinel Surveillance 2017, NACO, MoH&FW, GOI- Member
  3. Expert consultation -Newer Methods of Surveillance and HIV estimations in India UNAIDS,WHO and NACO, 2018
  4. National Consultation-Elimination of Mother to Child Transmission of HIV -Private Sector participation, NACO N Delhi
  5. Expert Consultation for HIV Surveillance and Estimations 2016: WHO and NACO, MoH&FW, GOI: Member and Resource Person
  6. National Core Group on Elimination of Mother to Child Transmission of HIV and Syphilis, constituted by NACO, MoH&FW, GOI: Member 2016 onwards
  7. Subcommittee for development of Verification and Validation protocols for Elimination of Mother to Child Transmission of HIV and Syphilis (EMTCT) constituted by NACO MoH&FW, GOI: Member
  8. Technical Resource Group for Prevention of Parent to Child Transmission of HIV, NACO, MoH&FW, GOI- Member
  9. National Strategic Plan (2017-24) (NACO road map) for prevention and elimination of HIV/AIDS in India constituted by NACO MoH&FW, GOI:  Technical Sub-Committee Monitoring, Evaluation and Surveillance: Member
  10. National Strategic Plan (2017-24) NACO road map for prevention and elimination of HIV/AIDS in India constituted by NACO MoH&FW, GOI:  Technical Sub-Committee for a. EMTCT of HIV & b. HIV-TB:  Member
  11. National HIV Testing Guidelines Writing Group: Technical Expert and Sub Committee member Dec 2015 – July 2016. The guidelines were published in Dec 2016
  12. National Expert Consultation for HIV Testing: WHO and NACO Nov 2015 Member
  13. National Expert Consultation for the Development of a Strategy towards Elimination of Congenital Syphilis (ECS) WHO and NACO 2013 : Member
  14. Regional STI Centre National Mentoring Committee: Committee was constituted in September 2012 onwards by NACO (MOHFW): Member
  15. Ethics Committee: UDIRT, Maharashtra University of Health Sciences (MUHS), Nashik, Maharashtra. February 2006-8: Member
  16. NACO Technical Resource Group’s for NACP IV planning: Member for the following sub-groups-
    1. Sexually Transmitted Infections Working group and STI Surveillance
    2. Research and Evaluation: Strategic Information Management Unit

 

International:

  1. Prevention Science Working Group- HIV Prevention Trial Network (completed)
  2. AIDS Clinical Trials Network Women’s Health Committee (completed)
  3. Women at Risk (WaTR) Scientific Committee of HIV Prevention Trial Network (completed)

 

Professional Bodies:

  1. Indian Association of Preventive & Social Medicine (IAPSM)- Life member
  2. Indian Association of Dermatologists, Venereologists and Leprologists (IADVL) - Life member
  3. Indian Medical Association- Life Member

 

Number of Publications : 78
List of Publications

Publications:
1. “Pregnancy rates and clinical outcomes among women living with HIV enrolled in HPTN
052, AIDS Care”Sahar Z. Zangeneh, Ethan A. Wilson, Surabhi Ahluwalia, Deborah J. Donnell,
Ying Q. Chen, Beatriz Grinsztejn, Marineide G. Melo, Sheela V. Godbole, Mina C.
Hosseinipour, Taha Taha, Johnston Kumwenda, Marybeth McCauley, Myron S. Cohen & Karin
Nielsen-Saines (2022) DOI: 10.1080/09540121.2022.2141187


2. “Diversity in HIV epidemic transitions in India: An application of HIV epidemiological metrices
and benchmarks”Pradeep KumarID1 , Chinmoyee Das , Arvind Kumar , Damodar Sahu, Sanjay
K. Rai, Sheela Godbole , Elangovan Arumugam , Lakshmi P. V. M. , Shanta Dutta , H.
Sanayaima Devi , Vishnu Vardhana Rao Mendu , Shashi Kant , Arvind Pandey, Dandu Chandra
Sekhar Reddy,  Sanjay Mehendale, Shobini Rajan
PLoS ONE 17(7): e0270886. https://doi.org/10.1371/ journal.pone.0270886


3. “Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the
WHO Solidarity randomised trial and updated meta-analyses”. - WHO Solidarity Trial
ConsortiumThe Lancet, www.thelancet.com Published online May 2,
2022 https://doi.org/10.1016/S0140-6736(22)00519-0

4. “Age-specific prevalence of anal and cervical HPV infection and high-grade lesions in 11 177
women by HIV status: a collaborative pooled analysis of 26 studies”.  Feixue Wei, Ningshao
Xia, Rebeca Ocampo, Marc T Goodman, Nancy A Hessol, Beatriz Grinsztejn, Ana P
Ortiz, Fanghui Zhao, Erna M Kojic, Rupert Kaul,Isabelle Heard, Imran O Morhason Bello, Anna-
Barbara Moscicki, Alexandra de Pokomandy, Joel M Palefsky, Luana L S Rodrigues, Racheal S
Dube Mandishora, Reshmie A Ramautarsing, Silvia Franceschi, Sheela V Godbole, Fernanda K
Tso, Lynette J Menezes, Chunqing Lin, Gary M Clifford The Journal of Infectious Diseases,
23 March 2022. jiac108, https://doi.org/10.1093/infdis/jiac108


5. “A randomized clinical trial of HPV test-and-treat as compared to cytology-based screening for
prevention of cervical cancer among women living with HIV: AIDS Clinical Trials Group
Protocol A5282”. Wilkin T, Chen H, Sahasrabuddhe V, Matining R, Mngqibisa R, Chinula L,
Mbilizi Y, Magure T, Omoz-Oarhe AE, Rassool M, Riviere C, Bhosale R, Godbole S, Naranjo
R, Coombs R, Michelow P, Godfrey C, Firnhaber C.Clin Infect Dis. 2022 Mar 16:ciac213. doi:
10.1093/cid/ciac213. Online ahead of print. PMID: 35294524


6. “Quantifying inadvertent data-duplication- findings from validation of antenatal-registration and
HIV testing data-sets from an Indian state” Sheela Godbole , Shweta Chidrawar , Suvarna Sane,
Yashika Bansal , Asha Hegde , Shilpa Bembalkar , Suchit Kamble , Megha Mamulwar , Shrikala
Acharya , Vijay Bawiskar , Laxmi Ramakrishnan , Yujwal Raj , Raman Gangakhedkar, Ashok
Kumar, D C S Reddy, Arvind Pandey, Tobi Saidel, Naina Rani, Nicole Seguy, K S Sachdeva .
International Journal of Epidemiology, September 2021, Vol 50, Issue Supplement _1

 

7. “Sexually transmitted infections among HIV serodiscordant partners: A secondary analysis of
HIV Prevention Trial Network 052” Maganizo B Chagomerana, Mina C Hosseinipour, Jose
Henrique Pilotto, Sharlaa Badal-Faesen, Mulinda Nyirenda, Emily Shava, Sheela V Godbole,
Victor Akelo, Suwat Chariyalertsak, Ravindre Panchia and Myron Cohen. International
Journal of STD & AIDS 2021 Jul DOI: 10.1177/09564624211030368.


8. “District-level HIV estimates using the spectrum model in five states of India, 2017” Kumar P,
Sahu D, Rajan S, Mendu VV, Das C, Kumar A, Chandra N, Camara B, Rai S, Arumugam
E, Godbole SV, Singh SK, Kant S, Pandey A, Reddy DC, Mehendale S.Medicine
2021;100:28(e26578).


9. “Repurposed antiviral drugs for COVID-19–interim WHO SOLIDARITY trial results” The
members of the writing and steering committees (H. Pan, R. Peto, A.-M. Henao-Restrepo, M.-P.
Preziosi, V. Sathiyamoorthy, Q. Abdool Karim, M.M. Alejandria, C. Hernández García, M.-P.
Kieny, R. Malekzadeh, S. Murthy, K.S. Reddy, M. Roses Periago, P. Abi Hanna, F. Ader, A.M.
Al-Bader, A. Alhasawi, E. Allum, A. Alotaibi, C.A. Alvarez-Moreno, S. Appadoo, A. Asiri, P.
Aukrust, A. Barratt-Due, S. Bellani, M. Branca, H.B.C. Cappel-Porter, N. Cerrato, T.S. Chow, N.
Como, J. Eustace, P.J. García, S. Godbole, E. Gotuzzo, L. Griskevicius, R. Hamra, M. Hassan,
M. Hassany, D. Hutton, I. Irmansyah, L. Jancoriene, J. Kirwan, S. Kumar, P. Lennon, G.
Lopardo, P. Lydon, N. Magrini, T. Maguire, S. Manevska, O. Manuel, S. McGinty, M.T. Medina,
M.L. Mesa Rubio, M.C. Miranda-Montoya, J. Nel, E.P. Nunes, M. Perola, A. Portolés, M.R.
Rasmin, A. Raza, H. Rees, P.P.S. Reges, C.A. Rogers, K. Salami, M.I. Salvadori, N. Sinani,
J.A.C. Sterne, M. Stevanovikj, E. Tacconelli, K.A.O. Tikkinen, S. Trelle, H. Zaid, J.-A.
Røttingen, and S. Swaminathan) New England Journal of Medicine(NEJM) online- 2 nd
December 2020 Print – February 2021


10. “Findings from the 2017 HIV estimation round & trend analysis of key indicators 2010-2017:
Evidence for prioritising HIV/AIDS programme in India” Damodar Sahu , Pradeep Kumar ,
Nalini Chandra, Shobini Rajan, D.K. Shukla, S. Venkatesh, Saritha Nair, Anil Kumar, Jitenkumar
Singh, Srikanth Reddy, Sheela Godbole, A. Elangovan, M.K. Saha, Sanjay Rai, P.V.M.
Lakshmi, T. Gambhir, Savina Ammassari, Deepika Joshi, Amitabh Das, Poonam Bakshi ,
Sabyasachi Chakraborty, Amol Palkar, S.K. Singh, D.C.S. Reddy, Shashi Kant, Arvind Pandey &
M. Vishnu Vardhana Rao. Indian J Med Res 151, June 2020, pp 562-570 DOI:
10.4103/ijmr.IJMR_1619_19


11. “Persons living with HIV continue to present late for care: A trend analysis from 2011 to 2015”.
Kadam AV, Bembalkar SC, Panchal NU,Mamulwar MS, Shete AV, Godbole SV.*. Indian J
Sex Transm Dis 2019; 40:133-8.


12. "Evaluation of key survey components of bio-behavioral surveillance among HIV high-risk
subpopulation in Western India" Brahme RG, Godbole SV, Gangakhedkar RR, Sachdeva KS,
Verma V, Risbud AR. Indian J Public Health 2019;63:305-12.


13. “Optimization of extraction of genomic DNA from archived dried blood spot (DBS): potential
application in epidemiological research & bio banking”. Kumar A, Mhatre S, Godbole S et al.
Gates Open Research 2019, 2:57 [version 3; peer review: 2 approved, 1 approved with
reservations] (https://doi.org/10.12688/gatesopenres.12855.3)


14. “Declining Trends in HIV Prevalence Among Women Attending Antenatal Care Clinics
Obfuscate the Continued Vulnerability of Adolescent Girls in Maharashtra, India (2005–2017)”
Brahme, Radhika; Godbole, Sheela*; Sonawale, Suvarna; Kadu, Chitra; Yadav, Rajesh; Dulhani,
Nisha; Lokhande, Amit; Kumar, Pradeep; Deoraj, Pramod; Acharya, Shreekala; Rajan, Shobini;
Venkatesh, Srinivas JAIDS Journal of Acquired Immune Deficiency Syndromes, September
1, 2019,82(1):e13-e17 Letters to the Editor


15. “Cervical determinants of anal HPV infection and high-grade anal lesions in women: a
collaborative pooled analysis”. Chunqing Lin, Jiri Slama, Paula Gonzalez, Marc T Goodman,
Ningshao Xia, Aimée R Kreimer, Ting Wu, Nancy A Hessol, Yurii Shvetsov, Ana P Ortiz,
Beatriz Grinsztejn, Anna-Barbara Moscicki, Isabelle Heard, María del Refugio González Losa,
Erna M Kojic, Maarten F Schim van der Loeff, Feixue Wei, Adhemar Longatto-Filho, Zizipho A
Mbulawa, Joel M Palefsky, Annette H Sohn, Brenda Y Hernandez, Katina Robison, Steve
Simpson Jr, Lois J Conley, Alexandra de Pokomandy, Marianne A B van der Sande, Racheal S
Dube Mandishora, Lays P B Volpini, Alessandra Pierangeli, Byron Romero, Timothy Wilkin,
Silvia Franceschi, Carmen Hidalgo-Tenorio, Reshmie A Ramautarsing, Ina U Park, Fernanda K
Tso, Sheela Godbole, Kathleen W M D’Hauwers, Borek Sehnal, Lynette J Menezes, Sandra A
Heráclio, Gary M Clifford. Lancet Infectious Diseases Published online June 13,
2019 http://dx.doi.org/10.1016/S1473-3099(19)30164-1


16. “Understanding racial diversities in Kaposi's sarcoma”. Sheela Godbole, Manisha Ghate,
Sanjay Mehendale. Indian Journal of Medical Research 149, March 2019, pp 319-321
DOI:10.4103/ijmr.IJMR_2164_18IJMR_2164_18


17. “Functional invariant Natural Killer T cells secreting cytokines are associated with non-
progressive HIV-1 infection but not with suppressive ART” Singh D, Ghate M, Godbole S,
Kulkarni S and Thakar M.  Frontiers in Immunology, (section T Cell Biology). 9:1152.
Doi:10,3389/fimmu.2018.01152. 24 May 2018


18. “Use of computer-assisted personal interviewing and information management system in a
survey among HIV high-risk groups in India: Strengths, weaknesses, opportunities, and threats
analysis” Brahme R, Godbole S, Gangakhedkar R, Sachdeva KS, Verma V, Risbud A. Indian J
Community Med 2018;43:107-12


19. “Productively infected CD4+ cells express higher Human telomerase reverse transcriptase levels
indicating a possible mechanism of persistence in HIV infection” Poonam Suryawanshi, Sheela
Godbole, Jyoti Pawar. Madhuri Thakar , Ashwini Shete Journal of Microbiology and
Immunology. First published: 25 March 2018 https://doi.org/10.1111/1348-0421.12585


20. “Differing HIV vulnerability among female sex workers in a high HIV burden Indian state”
Mamulwar M, Godbole S*, Bembalkar S, Kamble P, Dulhani N, Yadav R, et al. (2018). PLoS
ONE 13(2): e0192130. https://doi.org/10.1371/journal.pone.0192130


21. “HIV Drug Resistance in Adults Receiving Early Versus Delayed Antiretroviral Therapy:
HPTN 052” Palumbo PJ, Fogel JM, Hudelson SE, Wilson EA, Hart S, Hovind L, Piwowar-
Manning E, Wallis C ,  Papathanasopoulos MA, Morgado MG, Saravanan S, Tripathy S , Eron
JJ, Gallant JE, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Pilotto
JH, Kumwenda J, Akelo V, Godbole SV, Santos BR, Grinsztejn B, Panchia R, Chariyalertsak
S, Makhema J, Badal-Faesen S, Chen YQ, Cohen MS, Eshleman SH. Journal of Acquired
Immune Deficiency Syndromes (JAIDS) December 2017.DOI
10.1097/QAI.0000000000001623


22. “Antibiotic susceptibility pattern of Neisseria gonorrhoeae strains isolated from five cities in
India during 2013–2016” Sangeeta V. Kulkarni, Manju Bala Syeeda A. Muqeeth [...] Sheela V
Godbole* Journal of Medical Microbiology Dec 2017


23. “Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity-mediating
antibodies in HIV-infected Indian individuals”. Nehul S, Kulkarni A, Pawar S, Godbole S,  Ghate M, Thakar M. Infect Dis (Lond). 2017 Aug 4:1-9. doi:
10.1080/23744235.2017.1361547.


24. “Association of HIV diversity and virologic outcomes in early antiretroviral treatment” HPTN
052.” Palumbo PJ, Wilson EA, Piwowar-Manning E, McCauley M, Gamble T, Kumwenda N,
Makhema J, Kumarasamy N, Chariyalertsak S, Hakim JG, Hosseinipour MC, Gonçalves de Melo
M, Godbole SV, Pilotto JH, Grinsztejn B, Panchia R, Chen YQ, Cohen MS, Eshleman Sh, Fogel
JM. PLoS One. May 2017.


25. “Virologic outcomes in early antiretroviral treatment: HPTN 052”. Eshleman SH, Wilson
EA, Zhang XC, Ou SS, Piwowar-Manning E, Eron JJ, McCauley M, Gamble T, Gallant
JE, Hosseinipour MC, Kumarasamy N, Hakim JG, Kalonga B, Pilotto JH, Grinsztejn B, Godbole
SV, Chotirosniramit N, Santos BR, Shava E, Mills LA, Panchia R, Mwelase N, Mayer KH, Chen
YQ, Cohen MS, Fogel JM HIV Clinical Trials e-pub April 7 2017.


26. “Low immune activation is associated with higher frequencies of central memory T cell subset in
a cohort of Indian long term non-progressors”. Saxena V, Bichare S, Singh D, Ghate M, Godbole
S, Kulkarni S, Gangakhedkar R, Paranjape R, Thakar M. AIDS Res Hum Retroviruses 2017
Feb;33 (2):121-125. doi:10.1089/AID.2016.0210.


27. “CD1d restricted Natural killer T cells are preserved in Indian long term non progressors
(LTNPs)” Singh D, Ghate M, Godbole S, Kulkarni S, Thakar M Feb 2017 JAIDS J Acquir
Immune Defic Syndr. 2017. doi:10.1097/QAI.0000000000001322


28. “Indian Long-term Non-Progressors Show Broad ADCC Responses with Preferential
Recognition of V3 Region of Envelope and a Region from Tat Protein”.Kulkarni A, Kurle
S, Shete A, Ghate M, Godbole S, Madhavi V, Kent SJ, Paranjape R, Thakar M. Frontiers in
Immunology 8(14) · January 2017. DOI: 10.3389/fimmu.2017.00005


29. “Development of IFN- secretory ELISPOT based assay for screening of ADCC responses.”
Shete A, Suryawanshi P, Chavan C, Kulkarni A, Godbole S, Ghate M and Thakar M. Journal of
Immunological methods 2016 Dec 5.


30. “Fitting HIV Prevalence 1981 Onwards for Three Indian States Using the Goals Model and the
Estimation and Projection Package.”  Bhatnagar T, Dutta T, Stover J, Godbole S, Sahu D,
Boopathi K, Bembalkar S, Singh KJ, Goyal R, Pandey A, Mehendale SM. PLoS
One. 2016 Oct 6;11(10):e0164001.


31. "HIV and Cancer Registry Linkage identifies a Substantial Burden of Cancers in Persons with
HIV in India". Sheela V Godbole et al Medicine 95: 37, September 2016


32. “Antiretroviral Treatment for Prevention of HIV Transmission: The Final Results of the HIV
Prevention Trials Network (HPTN) 052 Trial”. M S. Cohen, Y.Q. Chen, M McCauley, T.
Gamble, M.C.Hosseinipour, N. Kumarasamy, J.G. Hakim, J.Kumwenda, B Grinsztejn, J.H.S.
Pilotto, S.V. Godbole., S.Chariyalertsak, B.R. Santos, K H. Mayer, I F. Hoffman, S.H. Eshleman,
E Piwowar-Manning, L. Cottle, X.C. Zhang, J. Makhema, L.A. Mills, J. Eron, J. Gallant,
D.Havlir, S. Swindells, V.Elharrar, D Burns, T.E.Taha, K.Nielsen-Saines, D Celentano, M.
Essex, S.E. Hudelson, A.D.Redd.and T. R. Fleming, for the HPTN 052 Study Team* New
England Journal of Medicine 18 July 2016 online first DOI: 10.1056/NEJMoa1600693


33. "HIV infected CD4+ T cells use T-bet dependent pathway for production of IL-10 upon antigen
recognition". Scandinavian Journal of Immunology 83(4):288-296 · May 2016 DOI:
10.1111/sji.12422. Shete A, Suryawanshi P, Godbole S, Pawar J, Paranjape R, Thakar M

 

34. “HIV drug resistance in adults failing early antiretroviral treatment”. JAIDS Journal of
Acquired Immune Deficiency Syndromes · February 2016 DOI: 10.1097 Fogel, Jessica M.;
Hudelson, Sarah E.; Ou, San-San; Hart, Stephen; Wallis, Carole; Morgado, Mariza G.;
Saravanan, Shanmugam; Tripathy, Srikanth; Hovind, Laura; Piwowar-Manning, Estelle Sabin,
Devin; McCauley, Marybeth; Gamble, Theresa; Zhang, Xinyi Cindy; Eron, Joseph J.; Gallant,
Joel E.; Kumwenda, Johnstone; Makhema, Joseph; Kumarasamy, Nagalingeswaran;
Chariyalertsak, Suwat; Dr.; Hakim, James; Badal-Faesen, Sharlaa; Akelo, Victor; Hosseinipour,
Mina C.; Santos, Breno Riegel; Godbole, Sheela V; Pilotto, Jose Henrique; Grinsztejn, Beatriz;
Panchia, Ravindre ; Mayer, Kenneth H.; Chen, Ying Q.; Cohen, Myron S.; Eshleman, Susan H


35. “Fallacy of Using Odds Ratio as A Measure Of Association In Prospective Studies.” Asian J Sc
Tech. 2015; 6(11):1990-92 30 Nov 2015. Rajneesh K Joshi, Monil Anurag Khera and Sheela V.
Godbole


36. “Predictors of Bisexual Behaviour among MSM Attending Intervention Sites May Help in
Prevention Interventions for This Bridge to the Heterosexual Epidemic in India: Data from HIV
Sentinel Surveillance” Godbole S, Sane S, Kamble P, Raj Y, Dulhani N, et al. (2014  PLoS
ONE 9(9): e107439. doi: 10.1371/journal.pone.0107439


37. “Prevalence of anal Human papillomavirus (HPV) infection among HIV-infected women from
India.” Sheela V. Godbole, Arati K. Mane, Shweta R. Chidrawar, Usha R. Katti, Shubhangi
Kalgutkar, Prachi V.Athavale, Jyoti S. Pawar, Manisha M. Ratnaparkhi, Mallika Alexander, Arun
R. Risbud, Ramesh S.Paranjape, JAIDS Journal of Acquired Immune Deficiency Syndromes
Published Ahead of Print a DOI: 10.1097/QAI.0000000000000328 5th Sep 2014


38. “Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of
HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial” B Grinsztejn,
M Hosseinipour, H Ribaudo, S Swindells, J Eron, Y Chen, L Wang, San-San Ou, M Anderson, M
McCauley, T Gamble, N Kumarasamy, J Hakim, J Kumwenda, J H S Pilotto, S V Godbole, S
Chariyalertsak, M Gonçalves de Melo, K H Mayer, S H Eshleman, E Piwowar-Manning, J
Makhema, L Mills, R Panchia, I Sanne, J Gallant, I Hoff man, T E Taha, K Nielsen-Saines, D
Celentano, M Essex, D Havlir, M S Cohen, and the HPTN 052-ACTG Study Team. Lancet
Infectious Diseases,Volume 14, Issue 4, Pages 281 - 290, April 2014
http://dx.doi.org/10.1016/S1473-3099(13)70692-


39. “Cost-Effectiveness of HIV Treatment as Prevention in Serodiscordant Couples” Rochelle P.
Walensky, M.D., M.P.H., Eric L. Ross, B.A., Nagalingeswaran Kumarasamy, M.B., B.S., Ph.D.,
Robin Wood, D.Sc., Farzad Noubary, Ph.D., A. David Paltiel, Ph.D., M.B.A., Yoriko M.
Nakamura, B.A., Sheela V. Godbole, M.D., Ravindre Panchia, M.B., B.Ch., Ian Sanne, M.B.,
B.Ch., D.T.M.&H., Milton C. Weinstein, Ph.D., Elena Losina, Ph.D., Kenneth H. Mayer, M.D.,
Ying Q. Chen, Ph.D., Lei Wang, Ph.D., Marybeth McCauley, M.P.H., Theresa Gamble, Ph.D.,
George R. Seage, III, D.Sc., M.P.H., Myron S. Cohen, M.D., and Kenneth A. Freedberg, M.D.N
Engl J Med 2013;369:1715-1725October 31, 2013


40. “Self-Report of STI Symptoms, Inconsistent Condom use and Condom Nonuse are Poor
Predictors of STI Prevalence among Men who have Sex with Men”. Nagarajan K, Godbole S*,
Ramakrishnan L, Mainkar MK, Ramesh S, Deepika Ganju Ramesh S Paranjape (2013) Journal
of AIDS & Clinical Research4:212. doi: 10.4172/2155-6113.1000212 2013


41. ‘Risk reduction and perceived collective efficacy and community support among female sex
workers in Tamil Nadu and Maharashtra, India: the importance of context.’ Mohua Guha,
Angela Baschieri, Shalini Bharat,Tarun Bhatnagar, Suvarna Sanjay Sane, Sheela V Godbole, Saravanamurthy P S,Mandar Keshav Mainkar, Joseph Williams, Martine Collumbien. JECH
Online First, published on July 3, 2012 as 10.1136/jech-2011-200562


42. ‘Current Status of Research on HIV Epidemic, Pathogenesis, Management and Prevention in
India.’ Ramesh S. Paranjape, Madhuri R. Thakar, Manisha V. Ghate and Sheela V. Godbole.
Proceedings of the National Academy of Sciences, India Section B 2012; 82(1): 167-180


43. ‘Sexually Transmitted Infections and Risk Behaviors among Transgender persons (Hijras) of
Pune, India’. Sahastrabuddhe S, Gupta A, Stuart E, Godbole S, Ghate M, Sahay S,
Gangakhedkar R, Risbud A, Divekar A, Bollinger R, Mehendale S. J Acquir Immune Defic
Syndr 2012 Jan 1; 59(1):72-8.


44. “Prevention of HIV-1 Infection with Early Antiretroviral Therapy.” Myron S. Cohen, Ying Q.
Chen, Marybeth McCauley, Theresa Gamble, Mina C. Hosseinipour, Nagalingeswaran
Kumarasamy, James G. Hakim, Johnstone Kumwenda, Beatriz Grinsztejn, Jose H.S. Pilotto,
Sheela V. Godbole., Sanjay Mehendale, Suwat Chariyalertsak, Breno R. Santos, Kenneth H.
Mayer, Irving F. Hoffman, Susan H. Eshleman, Estelle Piwowar-Manning, Lei Wang, Joseph
Makhema, Lisa A. Mills, Guy de Bruyn, Ian Sanne, Joseph Eron, Joel Gallant, Diane Havlir,
Susan Swindells, Heather Ribaudo, Vanessa Elharrar, David Burns,Taha E. Taha, Karin Nielsen-
Saines, David Celentano, Max Essex, and Thomas R. Fleming, for the HPTN 052 Study Team*
New England Journal of Medicine 2011, 10.1056/NEJMoa1105243) July 18, 2011, at
NEJM.org.


45. “Impact of Targeted Interventions on Heterosexual Transmission of HIV in India.” Rajesh
Kumar, Sanjay M Mehendale, Samiran Panda, S Venkatesh, Pvm Lakshmi, Manmeet Kaur,
Shankar Prinja, Tarundeep Singh, Navkiran K Virdi, Pankaj Bahuguna, Arun K Sharma,
Samiksha Singh, Sheela V Godbole, Arun Risbud, Boymkesh Manna, V Thirumagal, Tarun Roy,
Ruchi Sogarwal, Nilesh D Pawar. BMC Public Health 2011, 11:549


46. “Mortality in HIV infected individuals in Pune, India.” Manisha Ghate, Swapna Deshpande,
Srikanth Tripathy, Sheela Godbole, Madhura Nene, Madhuri Thakar, Arun Risbud, Robert
Bollinger & Sanjay Mehendale. Indian J Med Res 133, April 2011, pp 414-420


47. “Stigmatizing attitudes and low levels of knowledge but high willingness to participate in HIV
Management: A community-based survey of pharmacies in Pune, India.” Amita Gupta, Suvarna
S Sane, Ajay Gurbani, Robert C Bollinger, Sanjay M Mehendale, Sheela V Godbole. BMC
Public Health 2010, 10:51


48. “Incidence of common opportunistic infections in HIV-infected individuals in Pune, India:
analysis by stages of immunosuppression represented by CD4 counts.”Ghate M, Deshpande S,
Tripathy S, Nene M, Gedam P, Godbole S, Thakar M, Risbud A, Bollinger R, Mehendale S.
International Journal of Infectious Diseases.(2009)13, e1-e8


49. “HIV Infection in India : Epidemiology, molecular epidemiology and pathogenesis.” Samir
Lakhashe, Madhuri Thakar, Sheela Godbole, Srikanth Tripathy and Ramesh Paranjape.Journal
of Biosciences Nov 2008; 33 (4) : 515-525


50. “Biomedical research on HIV/AIDS in India.”Sheela Godbole& Sanjay Mehendale published on
the web at www.infochangeindia.org in Februay 2008.


51. “Declining HIV incidence among patients attending Sexually transmitted Infection Clinics in
Pune, India.” Sanjay M Mehendale, Nikhil Gupte, Ramesh Paranjape, Amita Gupta, Radhika
Brahme, Rewa Kohli, Neelam Joglekar , Sheela V Godbole, Smita N Joshi Manisha V Ghate,
Seema Sahay, B Kishore Kumar, Raman R Gangakhedkar, Arun R Risbud, Ron Brookemeyer,
Robert C Bollinger J Acquir ImmuneDefic Syndr, Aug 15 2007 (45),5, 564-569


52. “Issues in managing and coordinating clinical research in India.”Godbole, S.,& Ghate, M.
(2006).  Research Practitioner, 7(6), 219-220


53. “Same sex behaviour and high rates of HIV among men attending sexually transmitted infection
clinics in Pune, India, 1993-2002.” Amita Gupta, Shruti Mehta, Sheela V Godbole, Seema
Sahay, Louise Walshe, Steven J reynolds, Manisha Ghate, Raman R Gangakhedkar, Anand
Divekar, Arun R Risbud, Sanjay M Mehendale, Robert C Bollinger J Acquir ImmuneDefic
Syndr epub Oct 2 2006


54. “High Rates of Syphilis among STI Patients are Contributing to the Spread of HIV-1 In India.”
Steven. J Reynolds, Arun R. Risbud, Mary.E. Shepherd, Anne M. Rompalo, Manisha V. Ghate,
Sheela V. Godbole, Smita N Joshi, Anand D Divekar, Raman R. Gangakhedkar, Robert C.
Bollinger, and Sanjay M Mehendale. Sex Transm Infections 2006;82:121-126


55. “Rate of hospitalization and inpatient care costs for HIV-1 infected persons in Pune, India.”
Ghate MV, Tripathy SP, Kumar BK, Godbole SV, Chitakke A, NyanirguneP,Thakar MR,
Gangakhedkar RR, Divekar AD, Risbud AR, Bollinger RC, Mehendale SM. Nat Med J India
2006; 19(1):10-14


56. “Low HIV incidence among married serodiscordant couples in Pune, India.” Mehendale S M,
Ghate M V, Kumar BK, Sahay S, Gamble TR, Godbole SV, Thakar MR, Kulkarni SS, Gupta A,
Gangakhedkar RR, Divekar AD, Risbud AR, Paranjape RS, Bollinger RC, J Acquir
ImmuneDefic Syndr 2006; 41(3): 317-373


57. “High HIV Prevalence Among a High-Risk Subgroup of Women Attending Sexually Transmitted
Infection Clinics in Pune, India.” Shruti H Mehta, Amita Gupta, Seema Sahay, Sheela
VGodbole, Smita N Joshi, Steven J Reynolds, David D Celentano, Arun Risbud, Sanjay M
Mehendale, Robert C Bollinger. J Acquir ImmuneDefic Syndr. 2006 Jan; 41(1):75-80


58. “Phase I safety study of Praneem polyherbal vaginal tablet use among HIV-uninfected women in
Pune, India.”Joshi SN, Katti U, Godbole S, Bharucha K, B KK, Kulkarni S, Risbud A,
Mehendale S.Trans R Soc Trop Med Hyg. 2005 Oct; 99(10):769-74


59. “HIV/AIDS epidemic in India: risk factors, risk behaviours and strategies for prevention and
control.”Sheela Godbole& Sanjay Mehendale Indian J Med Res. 2005 Apr;121(4):356-68


60. “Fluconazole resistant non-albicans vaginal yeast in HIV seronegative women with vaginal
discharge in Pune, India.” R Kairon, S Godbole, S Kulkarni, M Ghate, S Sane, A Shrotri, K
Bharucha, S Mehendale, A Risbud. Int J Infect Dis. 2004 Jul; 8(4):251-2


61. “Agenda for Action: Research Priorities in HIV/AIDS in Maharashtra, India.”
a. A report for Avert Society Maharashtra: a Joint project of NACO, Govt. of Maharashtra
and USAID. Facilitators and Editors: Dr. Seema Sahay and Dr. Sheela Godbole

 

62. “Rate of hospitalization and inpatient care costs for HIV-1 infected persons in Pune, India.”
Ghate MV, Tripathy SP, Kumar BK, Godbole SV, Chitakke A, NyanirguneP,Thakar MR,
Gangakhedkar RR, Divekar AD, Risbud AR, Bollinger RC, Mehendale SM. Nat Med J India
2006; 19(1):10-14


63. “Low HIV incidence among married serodiscordant couples in Pune, India.” Mehendale S M,
Ghate M V, Kumar BK, Sahay S, Gamble TR, Godbole SV, Thakar MR, Kulkarni SS, Gupta A,
Gangakhedkar RR, Divekar AD, Risbud AR, Paranjape RS, Bollinger RC, J Acquir
ImmuneDefic Syndr 2006; 41(3): 317-373


64. “High HIV Prevalence Among a High-Risk Subgroup of Women Attending Sexually Transmitted
Infection Clinics in Pune, India.” Shruti H Mehta, Amita Gupta, Seema Sahay, Sheela
VGodbole, Smita N Joshi, Steven J Reynolds, David D Celentano, Arun Risbud, Sanjay M
Mehendale, Robert C Bollinger. J Acquir ImmuneDefic Syndr. 2006 Jan; 41(1):75-80


65. “Phase I safety study of Praneem polyherbal vaginal tablet use among HIV-uninfected women in
Pune, India.”Joshi SN, Katti U, Godbole S, Bharucha K, B KK, Kulkarni S, Risbud A,
Mehendale S.Trans R Soc Trop Med Hyg. 2005 Oct; 99(10):769-74

Dr. Sheela V Godbole MD 09 Jan 2023


66. “HIV/AIDS epidemic in India: risk factors, risk behaviours and strategies for prevention and
control.”Sheela Godbole& Sanjay Mehendale Indian J Med Res. 2005 Apr;121(4):356-68


67. “Fluconazole resistant non-albicans vaginal yeast in HIV seronegative women with vaginal
discharge in Pune, India.” R Kairon, S Godbole, S Kulkarni, M Ghate, S Sane, A Shrotri, K
Bharucha, S Mehendale, A Risbud. Int J Infect Dis. 2004 Jul; 8(4):251-2


68. “Agenda for Action: Research Priorities in HIV/AIDS in Maharashtra, India.”
A report for Avert Society Maharashtra: a Joint project of NACO, Govt. of Maharashtra and
USAID. Facilitators and Editors: Dr. Seema Sahay and Dr. Sheela Godbole


69. “Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized
clinical trial in diverse multinational settings”.Campbell TB, Smeaton LM, Kumarasamy
N, Flanigan T, Klingman KL, Firnhaber C, Grinsztejn B, Hosseinipour MC, Kumwenda J,Lalloo
U, Riviere C, Sanchez J, Melo M, Supparatpinyo K, Tripathy S, Martinez AI, Nair
A, Walawander A, Moran L, Chen Y, Snowden W,Rooney JF, Uy J, Schooley RT, De Gruttola
V, Hakim JG; PEARLS study team of the ACTG. PLoS Med. 2012 Aug;9(8):e1001290. Epub
2012 Aug 14. PMID: 22936892, PMCID: PMC3419182
a. *As a Study Team Member


70. Galvanizing Evidence for HIV Management: A Consultative Meet (NARI, Pune. 27-29 Jan
2011). A report compiled by Dhayarkar S, Krishnan S, Alexander M, Ghate M, Godbole S,
Gangakhedkar RR, Tripathy SP. NARI Bulletin April 2011; vol 2, Iss 2, pp 1-8.


71. Early ART (antiretroviral therapy) can prevent Sexual Transmission of HIV to uninfected partner
and benefit the infected person as well": Results from the HPTN 052 Study provide a prevention
option that seems like an optimal use of antiretroviral drugs for prevention! Godbole S, NARI
Bulletin Oct 2011, Vol 2, Iss 4, pp 8-11.

 

Books and Reports and Guidelines
72. COVID-19 PANDEMIC (History, Science & Society), Chapter 5 Arrows in the Quiver:
Prevention & Treatment Pages 66-85 Dr. Samiran Panda & Dr. Sheela Godbole, Published
by: The Director General, Publications Division Ministry of Information and Broadcasting,
Government of India, Soochna Bhawan, CGO Complex, Lodhi Road, New Delhi 03,
http://www.publicationsdivision.nic.in


73. Impact Evaluation of Antiretroviral Treatment Program in India. Report Commissioned
by National AIDS Control Organization (NACO) Ministry of Health and Family Welfare
Sep 2021


74. District-Level HIV Estimates and Prioritization in India 2019: Technical Brief, National
AIDS Control Organisation & ICMR-National Institute of Medical Statistics (2021). District-
Level HIV Estimates and Prioritization in India 2019: Technical Brief. New Delhi: NACO,
Ministry of Health and Family Welfare, Government of India. untitled (naco.gov.in)


75. India HIV Estimates 2020: Technical Brief National AIDS Control Organisation & ICMR-
National Institute of Medical Statistics (2021). District-Level HIV Estimates and Prioritization in
India 2019: Technical Brief. New Delhi: NACO, Ministry of Health and Family Welfare,
Government of India. untitled (naco.gov.in)

Dr. Sheela V Godbole MD 09 Jan 2023


76. Reopening Schools After COVID-19 Closures, Lancet COVID Commission, Published on
website April 2021
https://static1.squarespace.com/static/5ef3652ab722df11fcb2ba5d/t/60a3cff2b425ae21a5b49405/1621348
340073/India+TF+Reopening+Schools+April+2021.pdf


77. Country-wide Containment Strategies for Reducing COVID-19 Cases in India, Lancet
COVID Commission, Published on website April 2021
https://static1.squarespace.com/static/5ef3652ab722df11fcb2ba5d/t/60a3cf08d1c1f24480a44c19/1621348
107249/India+TF+Country-wide+Containment+Strategies+April+2021.pdf


78. Checklist: Containment Strategies for Reducing COVID-19 Cases in India , Lancet COVID
Commission, Published on website April 2021
https://static1.squarespace.com/static/5ef3652ab722df11fcb2ba5d/t/60a3ce9b7e2b69785d33f6e0/162134
7995814/India+TF+Checklist+April+2021.pdf


79. In country Data Validation, Elimination of Mother-to-Child Transmission of HIV and
Syphilis. A Report Commissioned by National AIDS Control Organization (NACO) Ministry of
Health and Family Welfare 2017 [Primary Author]


80. National HIV Counseling and Testing Services (HCTS) Guidelines [Writing Team]


81. India HIV Estimations 2017 Technical Report, National AIDS Control Organization & ICMR-
National Institute of Medical Statistics Ministry of Health & Family Welfare Government of
India


82. HIV Sentinel Surveillance 2016-17 Technical Brief, December 2017 National AIDS Control
Organization [ Regional Team Leader]


83. National Integrated Biological and Behavioural Surveillance (IBBS) 2014-15, High Risk
Groups in India


84. Report on INDO-US Joint Workshop on “HIV Database and Cancer Registry Match”


85. Newer Methods of HIV Prevention- Training Module in the one Year HIV Management
Certificate Course offered by IGNOU [Author]


Gene Sequences submitted to and published in NCBI gene bank:

Neisseria Gonorrhoeae: gyrA, parC, mtrR sequences

gyr A: NCBI accession number: KY347918 - KY348041,14-12-16
par C: NCBI accession number: KY348042 - KY348165, 14-12-16
mtrR :NCBI accession number: KY348166 - KY348289, 14-12-16